NAS:LMAT Key Ratios
| Market Cap $ M | 1,843.03 |
| Enterprise Value $ M | 1,657.05 |
| P/E(ttm) | 28.28 |
| PE Ratio without NRI | 30.94 |
| Forward PE Ratio | 25.35 |
| Price/Book | 4.38 |
| Price/Sales | 7.28 |
| Price/Free Cash Flow | 25.93 |
| Price/Owner Earnings | 31.27 |
| Payout Ratio % | 0.35 |
| Revenue (TTM) $ M | 262.00 |
| EPS (TTM) $ | 2.85 |
| Beneish M-Score | -2.76 |
| 10-y EBITDA Growth Rate % | 13.90 |
| 5-y EBITDA Growth Rate % | 15.40 |
| y-y EBITDA Growth Rate % | 31.40 |
| EV-to-EBIT | 18.43 |
| EV-to-EBITDA | 16.50 |
| PEG | 2.01 |
| Shares Outstanding M | 22.87 |
| Net Margin (%) | 25.03 |
| Operating Margin % | 29.46 |
| Pre-tax Margin (%) | 32.29 |
| Quick Ratio | 14.38 |
| Current Ratio | 16.31 |
| ROA % (ttm) | 10.73 |
| ROE % (ttm) | 16.74 |
| ROIC % (ttm) | 26.07 |
| Dividend Yield % | 1.18 |
| Altman Z-Score | 7.20 |
LMAT Number of Guru Trades
LMAT Volume of Guru Trades
Gurus Latest Trades with NAS:LMAT
NAS:LMAT is held by these investors
LeMaitre Vascular Inc Insider Transactions
Guru Commentaries on NAS:LMAT
LeMaitre Vascular, Inc. (LMAT) was the weakest performer in our portfolio, accounting for more than half of our total sector losses. Despite delivering a strong fundamental quarter with 10% organic revenue growth and gross margins of 72.1%, the shares declined following the earnings release as investors took profits in one of the medical device sector's strongest performers. We continue to believe the company is well positioned to generate attractive revenue and earnings growth over the coming years, supported by its differentiated vascular product portfolio and consistent execution.
LeMaitre Vascular, our peripheral vascular device holding, declined approximately 12% in a quarter when nearly everything profitable in small cap health care went down and nearly everything speculative went up. The company's niche leadership, pricing power, and consistent execution are unchanged, and we view the weakness as sentiment-driven rather than fundamental.
LeMaitre Vascular, Inc. (LMAT) continues to demonstrate its ability to convert steady procedure-driven demand into significant profit growth. The company achieved a 47% increase in operating income on mid-teens revenue growth, showcasing strong operating leverage. Investors have responded positively to LMAT's consistent execution and high visibility in a volatile market, reinforcing our belief in its durable growth characteristics and potential for long-term value creation.
News about NAS:LMAT
Total 0- 1
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
